Brush John E, Harper Ann M, Kohan Luke C, Bouker Zachary, Dandamudi Kaivalya, Talreja Deepak R
Sentara Health, Norfolk, VA, USA.
Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA, USA.
Am Heart J Plus. 2025 Apr 5;53:100540. doi: 10.1016/j.ahjo.2025.100540. eCollection 2025 May.
Acute myocardial infarction with cardiogenic shock (AMICS) carries high mortality and remains a major concern. This concern drives use of interventions with marginal benefit and some evidence of harm. The configuration of hospital care and allocation of interventions for AMICS in our health system created a natural experiment to analyze interventional outcomes for patients with AMICS.
To compare clinical outcomes among AMICS patients treated with mechanical circulatory support (MCS) using a micro-axial left ventricular assist device and intra-aortic balloon counter-pulsation (IABP).
In this observational study in a large health system, we used clinical registry data augmented with data from other sources to analyze 30-day and 180-day mortality as well as complications including major bleeding, and access site injury.
Of 505 patients with AMICS, 73 were treated with MCS and 160 with IABP. Baseline characteristics were similar between treatment groups except infarct location. Multivariable logistic regression showed that MCS was associated with 1.92 (CI = 1.10-3.37) times higher 30-day mortality risk and 2.03 (CI = 1.17-3.57) times higher 180-day mortality risk. In MCS-inclined hospitals as compared with IABP-inclined hospitals, patients had significantly higher 180-day mortality (45.3 % versus 33.9 %, = 0.017), and bleeding rates (15.1 % versus 1.3 %, < 0.001), with trends toward higher 30-day mortality (41.4 % versus 32.6 %, = 0.064) and access site injury (4.7 % versus 1.3 %, = 0.063).
In this real-world setting, MCS use for AMICS was associated with higher complication rates. Before using this device for AMICS, clinicians should consider tight selection criteria to minimize harm and maximize overall benefit.
急性心肌梗死伴心源性休克(AMICS)死亡率高,仍是一个主要问题。这一问题促使人们使用效益有限且有一些危害证据的干预措施。我们医疗系统中针对AMICS的医院护理配置和干预措施分配构成了一项自然实验,以分析AMICS患者的干预结果。
比较使用微轴左心室辅助装置进行机械循环支持(MCS)和主动脉内球囊反搏(IABP)治疗的AMICS患者的临床结局。
设计、设置、参与者、结局指标:在这项针对大型医疗系统的观察性研究中,我们使用临床登记数据以及来自其他来源的数据,分析30天和180天死亡率以及包括大出血和穿刺部位损伤在内的并发症。
在505例AMICS患者中,73例接受了MCS治疗,160例接受了IABP治疗。除梗死部位外,治疗组间基线特征相似。多变量逻辑回归显示,MCS与30天死亡风险高1.92倍(CI = 1.10 - 3.37)以及180天死亡风险高2.03倍(CI = 1.17 - 3.57)相关。与倾向于使用IABP的医院相比,倾向于使用MCS的医院中患者180天死亡率显著更高(45.3%对33.9%,P = 0.017),出血率也更高(15.1%对1.3%,P < 0.001),30天死亡率(41.4%对32.6%,P = 0.064)和穿刺部位损伤(4.7%对1.3%,P = 0.063)有升高趋势。
在这种实际情况下,AMICS使用MCS与更高的并发症发生率相关。在将该装置用于AMICS之前,临床医生应考虑严格的选择标准,以尽量减少危害并使总体获益最大化。